The 2016 Scientific Congress of the American Society for Reproductive Medicine (ASRM) is in full swing in Salt Lake City. Among the events of greatest interest to the Health Decisions contingent at the congress is “Advancing Science and Practice to Improve Access in Reproductive Care,” a workshop jointly sponsored by ASRM and the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD). The workshop begins tonight with a keynote lecture by Eli Adashi of Brown.
Workshop Addresses Untreated and Undertreated Infertility Patients
The workshop is of particular importance because, as highlighted by the ASRM Ethics Committee in November 2015, only 24% of the assisted reproductive technology (ART) needs in the US are being met: “…it seems apparent that many US women and men with impaired fecundity, or the threat thereof, go untreated or undertreated.” During the workshop, physicians, scientists, and other health professionals will engage in discussions to identify promising areas of future research.
Additional Sessions on Contraception, Postmenopausal Issues
Today’s program also includes a showcase on “Emerging Research in Contraception.” The quest to expand the range of acceptable options for contraception continues.
Today’s ASRM program also includes sessions on hormone therapy in postmenopausal women, postmenopausal sexuality, maximizing overall health to improve fertility outcomes and nonsurgical management of fibroids. The 2016 ASRM Scientific Congress shows progress in many areas, but also ample opportunity for drug and diagnostics developers to address unmet medical needs.
As a CRO focused on reproductive and women’s health, Health Decisions is looking forward to a busy 2017 assisting a variety of commercial and institutional sponsors in clinical studies of products with potential to improve diagnosis and treatment of millions of patients worldwide.
For example, we are pleased to be serving as Statistical and Clinical Coordinating Center for NICHD-sponsored contraception trials, including innovative trials in male hormonal contraception. We are also assisting commercial sponsors with trials of diagnostics and therapeutics for indications in maternal-fetal medicine, infectious disease and other indications.